知镜 Cognispect · 医学文献与研究工作台

The endothelin system: a potential target for the treatment of type 2 diabetes mellitus and associated cardiometabolic complications.

Sarker MMR, Islam MN, Simon NP, Islam T, Naser AZM, Hafez S, Hasan R.
Drug discovery today · 2026-09-25 · PMID 42790670

文献摘要

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance (IR), metabolic dysfunction, and cardiovascular (CV) and renal complications. Endothelin-1 (ET-1) receptors are widely expressed in insulin-sensitive tissues, including adipose tissue, skeletal muscle, and liver, which are both sources and targets of ET-1 action. Dysregulated ET-1 signaling promotes IR, altered glucose and lipid metabolism, inflammation, oxidative stress, and vascular dysfunction, contributing to obesity, CV complications, and multiorgan injury. In this review, we examine the role of ET-1 in T2DM complications, the indirect modulation of the ET system by established antidiabetic therapies, and the therapeutic potential of directly targeting ET-1 receptors and inhibiting ET-1 overproduction. We further discuss translational challenges and opportunities for combination therapies, biomarker-guided interventions, and precision ET-targeted approaches in cardiometabolic disease.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。